CD59 Antibody (B-3): sc-133171

CD59 Antibody (B-3) is a mouse monoclonal IgG2b antibody that detects CD59 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). CD59 is a glycosylphosphatidylinositol (GPI)-anchored protein predominantly found on the surface of leukocytes, vascular endothelial cells, various epithelial cells, and the placenta, playing a crucial role in the immune response. CD59 functions primarily as a regulator of the complement system, specifically inhibiting the formation of the membrane attack complex (MAC) by binding to the C8 and C9 components, thereby preventing lytic pore formation on host cell membranes. CD59′s location on the cell surface allows for immediate interaction with complement components, effectively protecting host cells from complement-mediated lysis during inflammatory responses. CD59 is involved in signaling pathways that drive calcium release and activate lipid-raft associated signaling molecules, including tyrosine kinases, which are vital for T cell adhesion and activation. The CD59 gene contains two p53-responsive domains, suggesting a potential role in protecting host cells from damage during inflammation, and indicating that p53 may influence the susceptibility of tumor cells to complement lysis during chemotherapy. Anti-CD59 antibody (B-3) is an essential tool for researchers studying immune regulation and the complement system in various biological contexts.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD59 Antibody (B-3) References:

1. The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias.  |  Ruiz-Argüelles, A. and Llorente, L. 2007. Autoimmun Rev. 6: 155-61. PMID: 17289551
2. CD59 incorporation protects hepatitis C virus against complement-mediated destruction.  |  Amet, T., et al. 2012. Hepatology. 55: 354-63. PMID: 21932413
3. Functional analysis of CD59 using complement-dependent cytotoxicity assay.  |  Kolev, M. 2014. Methods Mol Biol. 1100: 347-53. PMID: 24218274
4. Rapid degradation of the complement regulator, CD59, by a novel inhibitor.  |  Cai, B., et al. 2014. J Biol Chem. 289: 12109-12125. PMID: 24616098
5. CD59 signaling and membrane pores drive Syk-dependent erythrocyte necroptosis.  |  LaRocca, TJ., et al. 2015. Cell Death Dis. 6: e1773. PMID: 26018734
6. Increased levels of CSF CD59 in neuromyelitis optica and multiple sclerosis.  |  Uzawa, A., et al. 2016. Clin Chim Acta. 453: 131-3. PMID: 26686775
7. Cre-inducible human CD59 mediates rapid cell ablation after intermedilysin administration.  |  Feng, D., et al. 2016. J Clin Invest. 126: 2321-33. PMID: 27159394
8. A role for GPI-CD59 in promoting T-cell signal transduction via LAT.  |  Wang, LN., et al. 2018. Oncol Lett. 15: 4873-4881. PMID: 29541246
9. Soluble CD59 in peritoneal dialysis: a potential biomarker for peritoneal membrane function.  |  Faria, B., et al. 2021. J Nephrol. 34: 801-810. PMID: 33306183
10. Plasma glycated CD59 predicts postpartum glucose intolerance after gestational diabetes.  |  Benhalima, K., et al. 2021. Eur J Endocrinol. 185: 755-763. PMID: 34524975

The preferred CD59 antibody is CD59 Antibody (H-7): sc-133170.